Benitec appoints Kishen Mehta to board; Suvretta Capital portfolio manager

Benitec Biopharma Inc.

Appointed as Class I director effective June 26, 2024, term through 2026 annual meeting.
Mehta is portfolio manager at Suvretta Capital, which led $40M PIPE financing in April 2024.
Will serve on Nominating and Corporate Governance Committee; board deemed him independent.
Also serves on Biohaven Pharmaceuticals board; 15+ years healthcare investing experience.
Appointment follows Board Designation Agreement with Suvretta disclosed in prior 8-K.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kishan Mehta

Director

BNTC · Benitec Biopharma Inc.

Effective: 2024-06-26
Filed: July 1, 2024, 7:59 PM ET

On June 26, 2024, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed Kishan (“Kishen”) Mehta to serve as a director of the Board, effective as of June 26, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kishan Mehta was appointed as Director at Benitec Biopharma Inc..

Action: appointed
Role: Director

Exact text from the filing

On June 26, 2024, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed Kishan (“Kishen”) Mehta to serve as a director of the Board, effective as of June 26, 2024.

View on SEC.gov

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-173338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.